As of May 23
| -0.35 / -0.72%|
The 29 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 56.18, with a high estimate of 69.57 and a low estimate of 31.83. The median estimate represents a +16.38% increase from the last price of 48.27.
The current consensus among 30 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.